Shahrami Bita, Davoudi-Monfared Effat, Rezaie Zahra, Gheibi Shayesteh, Vakili-Ardabili Ayda, Arabzadeh Amir Ahmad, Talebi Ali, Mojtahedzadeh Mojtaba
Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Department of Anesthesiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Respir Med Case Rep. 2022;36:101611. doi: 10.1016/j.rmcr.2022.101611. Epub 2022 Feb 18.
A 78-year-old man with COVID-19 infection was admitted. Initial echocardiography indicated left ventricular ejection fraction (LVEF) of 15%, high pulmonary arterial pressure, severe left ventricular dysfunction, mild diastolic dysfunction, mild regurgitation mitral valve, and normal septal thickness. Considering the probable diagnosis of COVID-19-related myocarditis, the patient was early managed with the antivirals, immunomodulatory agents, a high dose of ascorbic acid, melatonin, and immunoglobulin therapy. His clinical condition was improved and his last echocardiography revealed LVEF of 40% and improvement in systolic and diastolic dysfunction. The clinicians should be aware of the potentially lethal cardiac complication of COVID-19, especially in geriatrics.
一名78岁的新冠肺炎感染男性患者入院。初始超声心动图显示左心室射血分数（LVEF）为15%，肺动脉高压，严重左心室功能障碍，轻度舒张功能障碍，二尖瓣轻度反流，室间隔厚度正常。考虑到可能诊断为新冠肺炎相关心肌炎，该患者早期接受了抗病毒药物、免疫调节剂、高剂量维生素C、褪黑素和免疫球蛋白治疗。他的临床状况有所改善，最后一次超声心动图显示LVEF为40%，收缩和舒张功能障碍有所改善。临床医生应意识到新冠肺炎潜在的致命心脏并发症，尤其是在老年患者中。
